Tejaswi Kanala MD
@TSKanala
Followers
833
Following
8K
Media
170
Statuses
1K
RadOnc | Fellow @MDAndersonNews | @RadOncTMC, OsmaniaMed alum | @CanGenetics_TMC | Organ preservation & Radiobiology | opinions my own |
Houston, TX
Joined November 2018
RT @DrMHofman: "Many lives are lost not because they don't have access to newest technology or drugs, but because they didn't receive prove….
0
13
0
So thankful Dr @drdavidpalma chose to rejoin X. This is a great story and an interesting walk through time.
I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️
0
0
16
RT @ArchyaDasgupta: PRIDE study proton RCT in adults with primary brain tumors (NCT06831461) is now live with the accrual of the first pati….
researchsquare.com
Background: Radiation therapy (RT) plays a significant role in the multimodal management of primary brain tumors, improving oncological outcomes. However, despite advances such as Intensity-Modulated...
0
6
0
RT @jryckman3: @Dan_ChangMD @UMichRadOnc Wow. That is pretty amazing! I love mine but you may have me beat!
0
1
0
RT @snakagawa_md: Before you see the patient, you spent time and looked up. You know where he lives and who he lives with. Then don't ask….
0
3
0
RT @Manishbhandare4: We report one of the largest series of signet ring cell carcinoma of the ampulla of Vater, post resection. 🔑Presence….
link.springer.com
Langenbeck's Archives of Surgery - Signet ring cell carcinoma (SRCC) of the ampulla of Vater is a rare histology with very limited data. In the present study, we report the outcomes of this...
0
15
0
RT @NiuSanford: 🚨Study activated!. NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100). Here's a short (….
0
43
0
RT @George_E_Naoum: @PTarantinoMD This is NOT true as the major driving risk factor for lymphedema is NOT nodal radiation it is Axillary su….
0
6
0
RT @KrishanJethwa: 🚨ESOPEC, Patterns of Recurrence🚨. 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%)….
0
39
0
RT @oncology_bg: Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronge….
0
64
0
RT @RadOncTMC: Honored to share highlights of @ReenaEngineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for loc….
0
56
0
RT @fumikochino: "All treatments are 'tolerable' . if you don't ask people who they feel.". Dr @DrDawnHershman getting #ASCO25's highest h….
0
21
0
Dr @ReenaEngineer from @RadOncTMC presents results from Ph3 randomised POLCA-GB trial for LA Gall Bladder Ca #ASCO25 . Addition of NACRT to NACT shows.✅Better response to Neoadjuvant Rx.✅Higher R0 resection rates.✅Higher EFS (4.9 Vs 10.6 mos).✅Higher OS (10.1 Vs 21.8 mos)
0
7
33
Dr @StevenLin_MDPhD of @MDAndersonNews making a case for all-radiation-is-not-same-radiation in the context of organ preservation in oesophageal cancer and a brief look at where we are headed in this space #ASCO25.
1
3
26
RT @ReenaEngineer: Honored to present the results of POLCA GB Trial of neoadjuvant chemoradiation vs chemotherapy alone in borderline respe….
0
6
0
RT @GIMedOnc: @NiuSanford I’m having trouble enrolling to oligomet trials myself. When i discuss it with patients and offer randomization t….
0
3
0
RT @MarkMishraMD: #ASCO25: In LA gallbladder CA, adding CRT to neoadjuvant chemo doubled OS (21.8 vs 10.1 mo, p=0.006) & ↑ R0 resection rat….
0
11
0
Had a patient tell me that she named her cancer(s) - Timmy the tumour, Nancy the node, and Larry the lump. I hope the AJCC’s taking🗒️because the time is now for a big update📝.
1
0
27
RT @cancerphysicist: PLATO ACT 4 results for dose de-escalation in early-stage anal cancer are out! Prof Sebag-Montefiore presents on the p….
0
20
0